Molecular pathology and targeted therapy of clear cell renal cancer;A világossejtes veserák célzott terápiá ja és molekuláris patológiai alapjai

Magyar Onkologia

Volumn 50, Issue 4, 2006, Pages 309-314

  Tímár, József ^a   Kopper, László ^b   Bodrogi, István ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE;

ADENOCARCINOMA; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; PATHOLOGY; PREDICTION AND FORECASTING; REVIEW;

ADENOCARCINOMA, CLEAR CELL; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; ENZYME INHIBITORS; HUMANS; KIDNEY NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34248547900     PISSN: 00250244     EISSN: 20600399     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Adnane L, Traill PA, Taylor I, Wilhelm SM. Sorafinib (BAY 43-9006, Nexavar (R), a dual-action inhibitor that targets FAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407:597-612, 2005
2. Beeram M, Rowinsky EK, Weiss GR, et al. Durable disease stabilization and antiumor activity with OSI-774 in renal cell carcinoma: A phase II, pharmacokinetic (PK) and biological correlative study with FGD-PET imaging. J Clin Oncol 22(Suppl 15):3050, 2004
3. Beniers AJ, Peelen WP, Debruyne FM, Schalken JA. HLA-class-I and -class-II expression on renal tumor xenografts and the relation to sensitivity for alpha-IFN, gamma-IFN and TNF. Int J Cancer 48: 709-716, 1991
4. Bromwich E, McMillan DC, Lamb GW, et al. The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer. Br J Cancer 91:1236-1238, 2004
5. Chuang ST, Chu P, Sugimura J, et al. Overexpression of glutathione-s-transferase alpha in clear cell renal cell carcinoma. Am J Clin Pathol 162:925-932, 2005
6. Drevs J, Müller-Driver R, Witting C, et al. PTK787/ZK 222584, a specific vascular endothelial growth factorreceptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 62:4015-4022, 2002
7. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Tumors of kidney. In: WHO Classification of Tumours. Tumours of the urinary system and male genital organs. IARC Press, Lyon, France, 2004
8. Elaraj DM, White DE, Steinberg SM, et al. A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. J Immunother 27:259-264, 2004
9. Hainsworth JD, Sosman JA, Spigel DR, et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23:7889-7896, 2005
10. Hedberg Y, Ljungberg B, Roos G, Landberg G. Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray. Br J Cancer 88:1417-1423, 2003
11. Higgins JP, Shinghal R, Gill H, et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol 162:925- 932, 2003
12. Hudes G, Carducci M, Tomczak P, et al. Temsirolinus, interferon-A plus temsirolinus for patients with advanced renal cell carcinoma and poor prognostic features. N Engl J Med, 2006 (in press)
13. Jacobsen J, Grankvist K, Rasmuson T, et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 93:297-302, 2004
14. Jermann M, Stahel RA, Salzberg M, et al. A phase II, openlabel study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal cell carcinoma. Cancer Chemother Pharmacol 57:533-559, 2006
15. Kopper l, Tímár J. Genomics of renal cell cancer - Does it provide breakthrough? Pathol Oncol Res 12:5-11, 2006
16. Lin F, Yang W, Betten M, et al. Expression of S-100 protein in renal cell neoplasms. Hum Pathol 37:462-470, 2006
17. Ljungberg BJ, Jacobsen J, Rudolfsson SH, et al. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma. BJU Int 98:661-667, 2006
18. Lorincz T, Tímár J, Szendroi M. Alterations of microvascular density in bone metastases of adenocarcinoms. Pathol Oncol Res 10:149-153, 2004
19. Mancuso A, Sterngberg CN. New treatment for metastatic kidney cancer. Can J Urol 12(Suppl 1):66-70, 2005
20. Motzer R, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24, 2006
21. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516-2524, 2006
22. Na X, Wu G, Ryan CK, et al. Overproduction of vascular endothelial growth factor related to von Hippel Lindau tumor suppressor gene mutations and hypoxiainducible factor-1 alpha expression in renal cell carcinomas. J Urol 170:588-592, 2003
23. Negrier S, Perol D, Menetier-Caux C et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: Prognostic value of interleukin- 6 - from the Groupe Francais d'Immunothérapie. J Clin Oncol 22:2371-2378, 2004
24. Ottó Sz, Kásler M. A hazai és nemzetközi daganatos halálozási és megbetegedési mutatók alakulása. A népegészségügyi programok jellegzetességei és várható eredményei. Magyar Onkológia 49:99-107, 2005
25. Padrik P. Prognostic factors of immunotherapy in metastatic renal cell carcinoma. Med Oncol 20:325-334, 2003
26. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: Exploiting the hypoxia-induced pathway. Clin Cancer Res 9:4641-4652, 2003
27. Patel PH, Chaganti RSK, Morzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 94:614- 619, 2006
28. Polite BN, Desai AA, Manchen B, Stadler WM. Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: Results of a single-institution phase II trial. Clin Genitourin Cancer 4:257-280, 2006
29. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebocontrolled randomized discontinuation trial of sorafinib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:4669-4670, 2006
30. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23:1028-1043, 2005
31. Rini BI, Jaeger E, Weinberg V. clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: Impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int 98:756-762, 2006
32. Royston P, Sauerbrei W, Ritchie A. Is treatment with interferon- A effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions. Br J Cancer 90:794-799, 2004
33. Rugo HS, Herbst R, Lin G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patient with advanced solid tumors: Pharmacokinetic and clinical result. J Clin Oncol 23:5474-5483, 2005
34. Sakaeda T, Okumura N, Gotoh A, et al. EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients. Pharm Res 22:1757-1761, 2005
35. Schuetz AN, Yin-Goen Q, Amin MB, et al. Molecular classification of renal tumors by gene expression profiling. J Mol Diagn =:206-218, 2005
36. Sternberg CN. Pazopanib (GV 780604): Phase 1 and clinical development. The First European International Kidney Cancer Symposium, Madrid, Spain, 2006
37. Takahashi M, Yang XJ, Sugimura J, et al. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene 22:6810-6818, 2003
38. Tsuchiya N, Sato K, Akao T, et al. Quantitative analysis of gene expression of vascular endothelial growth factorrelated factors and their receptors in renal cell carcinoma. Tohoku J Exp Med 195:101-113, 2001
39. Uhlman DL, Nguyen P, Manivel JC, et al. Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: Correlation with metastatic behavior and prognosis. Clin Cancer Res 1:913-920, 1995
40. Vuky J, Fotoohi M, Isacson C, et al. Phase II trial of imatinib mesylate (formerly known as STI-571) in patients with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 22:1672, 2003 (abstract)
41. Wittnebel S, Jalil A, Thiery J, et al. The sensitivity of renal cell carcinoma cells to interferon alpha correlates with p53-induction and involves Bax. Eur Cytokine Netw 16:123-127, 2005
42. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
43. Yang JC. Bevacizumab for patients with metastatic renal cancer: An update. Clin Cancer Res 10:6367S-6370S, 2004
44. Yao M, Tabuchi H, Nagashima Y, et al. Gene expression analysis of renal carcinoma: Adipose differentiation related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J Pathol 205:377-387, 2005
45. Young AN, de Oliveira Salles PG, Lim SD, et al. Beta defensin-1, parvalbumin and vimentin: A panel from gene expression profiling studies using cDNA microarrays. Am J Surg Pathol 27:199-205, 2003